Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Sarcoma × lenvatinib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 10 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Melanoma 6 Neoplasms 5 Carcinoma, Renal Cell 5 Neoplasm Metastasis 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Small Cell Lung Carcinoma 2 Ovarian Neoplasms 2 Liver Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Non-Small-Cell Lung 2 Advanced Solid Tumor 2 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Metastatic Castration-Resistant Prostate Cancer 1 Liposarcoma 1 Leiomyosarcoma 1

Interventions

Gemcitabine 12 Doxorubicin 11 pembrolizumab 10 Radiotherapy 10 Docetaxel 7 Nivolumab 6 Cyclophosphamide 6 pazopanib 5 Filgrastim 5 Ifosfamide 4 130-nm albumin-bound paclitaxel 4 eribulin 3 Vinorelbine 3 Temozolomide 3 Sirolimus 3 PM 01183 3 Irinotecan 3 Ipilimumab 3 Imatinib Mesylate 3 Drug Therapy 3 Albumin-Bound Paclitaxel 3 talimogene laherparepvec 2 surufatinib 2 selinexor 2 repotrectinib 2 poly ICLC 2 pegfilgrastim 2 liposomal doxorubicin 2 avelumab 2 atezolizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡